MTP looks to Simponi to secure dominant rheumatoid arthritis position in Japan
This article was originally published in Scrip
Executive Summary
Mitsubishi Tanabe Pharma (MTP) is expecting Simponi (golimumab) to help it maintain the leading position in the rheumatoid arthritis sector in Japan, where the subcutaneously injected TNF-alpha inhibitor has become the first once-monthly therapy in this class to be launched in the country.